Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Down 15.7% – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) fell 15.7% on Friday. The stock traded as low as $36.80 and last traded at $36.80. Approximately 500 shares traded hands during trading, a decline of 81% from the average daily volume of 2,647 shares. The stock had previously closed at $43.66.

Analyst Ratings Changes

A number of analysts recently issued reports on ZLDPF shares. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Barclays cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Zacks Research raised shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, September 11th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Get Zealand Pharma A/S alerts:

Get Our Latest Stock Analysis on ZLDPF

Zealand Pharma A/S Trading Up 5.0%

The stock’s fifty day moving average price is $46.78 and its 200 day moving average price is $46.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. The stock has a market capitalization of $2.86 billion, a P/E ratio of 6.63 and a beta of 0.95.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.

Featured Articles

• Five stocks we like better than Zealand Pharma A/S
• Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
• Target’s Holiday Blitz: Slashing Prices to Capture Market Share
• NIO Inc.’s Geely Deal Is Really a Bet on Battery-Swap Network Utilization
• Remitly’s September Pullback Tests a Still-Strong Growth Story

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.